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Abstract
● AIM: To evaluate the inhibitory effect of subconjunctival 
bevacizumab as single- and multiple-dose application, and 
compare their effects on corneal neovascularization in a 
rat model.
● METHODS: Thirty adult Sprague-Dawley rats were used 
in this experimental study. The central cornea of the rats 
was cauterized chemically. The rats were randomly enrolled 
into three groups. All groups received subconjunctival 
injections. In Group 1 (control group, n=10), 0.05 mL 0.9% 
NaCl solution was injected on the first day. In Group 2 
(single-dose group, n=10), 0.05 mL bevacizumab (1.25 mg) 
was injected on the first day. In Group 3 (multiple-dose 
group, n=10), four doses of 0.05 mL bevacizumab (1.25 
mg) were injected on the first, third, fifth and seventh day. 
Slit-lamp examination of all rats was performed at the third 
and ninth day. Digital images of the corneas were taken 
and analyzed using image analysis software to calculate 
corneal neovascularization area. All rats were sacrificed 
on the tenth day. In corneal sections, the number of blood 
vessels, state of inflammation and collagen formation was 
evaluated histopathologically.
● RESULTS: In Group 3, corneal edema grades were 
significantly lower than Group 1 and Group 2 (P=0.02, 
and P=0.035, respectively). The mean percentage of 
neovascularized corneal area in Group 3 was significantly 
lower than Group 2 (P=0.005). On histopathological 
examination, Group 2 and Group 3 showed significantly less 
number of blood vessels than Group 1 (P=0.005, and P=0.001, 
respectively). Additionally, Group 3 showed significantly less 
number of blood vessels compared to Group 2 (P=0.019). 
Inflammation and edema grades were significantly lower in 
Group 3 compared to Group 1 (P=0.001).
● CONCLUSION: Subconjunctival bevacizumab injection 
is effective in inhibition of newly formed corneal 
neovascularization. The multiple-dose bevacizumab treatment 
seems to be more effective compared to single-dose treatment.
● KEYWORDS: cornea; corneal neovascularization; bevacizumab; 
inflammation; rat
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INTRODUCTION
C ornea is a transparent connective tissue, as it’s clarity is related to the anatomic factors including avascularity of 
cornea, regular arrangement of the collagen fibers and balance 
between different layers and cellular components[1]. Corneal 
neovascularization is one of the reasons that may cause loss of 
optimal vision by damaging its transparency[2]. Inflammatory, 
infectious, traumatic and degenerative disorders may lead to 
new vessel formations in cornea resulting in decreased visual 
acuity. Therefore, in related corneal disorders new treatment 
options are needed to maintain corneal avascularity[3].
The avascular character of cornea results from a balance 
between angiogenic and anti-angiogenic factors[3-4]. Vascular 
endothelial growth factor (VEGF) has shown to be associated 
with corneal neovascularization[3,5]. Expression of VEGF receptors 
(Flt-1 and Flk-1) was also increased on endothelial cells of newly 
formed vessels in the stroma of inflamed corneas[5]. The secreted 
VEGF-A growth factor peptides are generated by alternative 
splicing into some isoforms including VEGF115, VEGF121, 
VEGF165, VEGF189, and VEGF206[6]. The other VEGF 
members include VEGF-B, VEGF-C, and VEGF-D, which bind 
differentially to VEGF receptors[6]. VEGF members stimulate 
both angiogenesis and lymphangiogenesis[5-6].
Some medical therapies including steroids, cyclosporin A, 
methotrexate, thalidomide have been used in the treatment 
of corneal neovascularization[7-10]. However, currently 
there is no proven available therapeutic method for corneal 
neovascularization[7-11]. Bevacizumab is a recombinant 
humanized monoclonal IgG1 antibody that specifically 
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binds to and neutralizes biological activity of VEGF-A and 
inhibits corneal neovascularization by binding all isoforms 
of VEGF-A[11-12]. VEGF inhibition has been shown to reduce 
corneal neovascularization[12-13]. In several studies both 
clinically and experimentally, bevacizumab has been used 
effectively for the treatment of corneal neovascularizaton[11-13]. 
However, there is no treatment protocol agreed upon[12-13].
Hence in this study, we aimed to evaluate and compare the 
inhibitory effects of single-dose and multiple-dose subconjunctival 
bevacizumab injection on corneal neovascularization in a rat 
model.
MATERIALS AND METHODS
Thirty eyes of thirty adult male Sprague-Dawley rats 
weighing 350-450 gram were used in this study. Approval 
of the experimental protocol was obtained from the Baskent 
University Medical School Research and Ethics Committee 
(DA 15/11). The animals were treated and maintained in 
accordance with the tenets of the Association for Research 
in Vision and Ophthalmology (ARVO) Statement for Use of 
Animals in Ophthalmic and Vision Research. The rats were 
placed in individual plastic cages in temperature-controlled 
room (22℃) where 12-12h light-dark circle was maintained. 
Proper food and water was provided for rats. 
For general anesthesia ketamine hydrochloride (50 mg/kg 
body weight) was administered intraperitoneally. Following 
topical anesthesia by 0.5% proparacaine hydrochloride, 
corneal neovascularization was induced with silver nitrate 
cauterization. In all right eyes of 30 rats, central area of each 
cornea was cauterized by the same investigator (Ulas B) 
via pressing a stick coated with 75% silver nitrate and 25% 
potassium nitrate for 10s under operating microscope. Cornea 
and fornices were then rinsed with 10 mL of balanced salt 
solution to remove excess silver nitrate and potassium nitrate. 
The rats were randomly enrolled into three groups, and all rats 
received subconjunctival injection at the first day following 
cauterization. In Group 1 (control group, n=10), 0.05 mL 0.9% 
NaCl solution was injected. In Group 2 (single-dose group, 
n=10), 0.05 mL bevacizumab (1.25 mg) was injected. In 
Group 3 (multiple-dose group, n=10), four doses of 0.05 mL 
bevacizumab (1.25 mg) were injected subconjunctivally on 
the third, fifth and seventh day, in addition to the first day. The 
subconjunctival injections were performed 1-mm behind the 
limbus at the same time, of the day by a 30-gauge needle.
Slit-lamp examination of all rats was performed on the third 
and ninth day. On the third day, using similar method of 
Monzano et al[14], the extent of burn stimulus response was 
graded for each cornea via slit-lamp as: grade 0 (no blister, not 
raised above the corneal surface); grade 1 (small blister, raised 
slightly above the surface); grade 2 (medium blister, raised 
moderately above the surface); grade 3 (large blister); grade 4 
(much wider and larger blister).
At the examination on the ninth day, corneal edema and 
corneal opacity grades were evaluated based on biomicroscopic 
examination by the way described by Yoeruek et al[15]. Corneal 
opacity was graded for each cornea as: grade 0 (transparent); 
grade 1 (minimal haze, details of iris and pupil distinct); grade 
2 (mild haze, iris and pupil detectable); grade 3 (moderate 
haze, iris and pupil hardly visible); grade 4 (opaque, iris and 
pupil not discernable)[15]. Corneal edema was graded for each 
cornea as: grade 0 (no edema); grade 1 (mild to moderate 
edema); grade 2 (severe edema)[15]. 
On the tenth day, digital images of the corneas were taken 
and analyzed using image-analysis software (Topcon Image 
Net 2000 Itabashik, Tokyo, Japan) to calculate corneal 
neovascularization area. The area of neovascularization 
was measured in terms of pixels, and its ratio to the entire 
corneal area was determined as the percentage of corneal 
neovascularization[14].
All rats were sacrificed on tenth day, and globes were enucleated 
for histopathologic examination by same investigator 
(Ulas B) as described by Oner et al[16]. Eyes were kept in 
10% formaldehyde for 24h. Corneas were embedded into 
paraffin and stained with hematoxylin and eosin and Masson 
trichrome[16]. Five-micron sections were taken from each 
cornea[16]. The corneal quadrants were evaluated with 400 
times magnification, and the number of blood vessels, degree 
of inflammation and collagen formation were compared[16]. In 
addition, the pathologist of our study (Bal N), described and 
graded corneal inflammation (hematoxylin and eosin) and 
corneal collagen formation (Masson trichrome) as following. 
Inflammation was graded for each cornea as: grade 0 (no 
inflammation); grade 1 (mild to moderate inflammation); 
grade 2 (severe inflammation). Collagen formation was also 
graded for each cornea as: grade 0 (regular); grade 1 (minimal 
separation and disruption); grade 2 (severe disruption).
All statistical analysis was performed using SPSS (Statistical 
Package for Social Sciences, SPSS 17.0 for Windows, USA). 
For the comparison of categorical variables, the Chi-square 
test or Fisher’s exact test was used. Kruskal-Wallis and 
Mann-Whitney U test was used to compare the continuous 
measurements between groups, P<0.05 was considered 
statistically significant.
RESULTS
The degree of corneal neovascularization is shown in Figure 1. 
All groups had corneal burn grades of 3 and 4. The corneal 
burn grade was not statistically different among the groups 
(P=0.873).
Corneal opacity grade was statistically significantly lower in 
multiple-dose bevacizumab treatment group (Group 3) than 
single-dose bevacizumab treatment group (Group 2), and 
control group (Group 1) (P=0.004, and P=0.0001, respectively). 
Although there was no statistical significance, corneal opacity 
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grade of single-dose bevacizumab group (Group 2) was lower 
than control group (Group 1, P=0.218; Table 1).
The corneal edema grade was least in multiple-dose 
bevacizumab treatment group, followed by single-dose 
bevacizumab treatment group, and control group (Table 2). 
Corneal edema grade was statistically significantly lower in 
multiple-dose bevacizumab treatment group than single-dose 
bevacizumab treatment group, and control group (P=0.035, 
and P=0.02, respectively). 
The mean±standard deviation (SD) percentage of neovascularized 
area was 68±5 percent in control group, 59±7 percent in single-
dose bevacizumab treatment group, and 47±10 percent in 
multiple-dose treatment group (Figure 2). The mean percentage 
of neovascularized area was significantly lower in single and 
multiple-dose bevacizumab treatment groups than control 
group (P=0.004, and P=0.0001, respectively). Additionally, 
the percentage of neovascularization was significantly lower 
in multiple-dose bevacizumab treatment group compared with 
single-dose bevacizumab treatment group (P=0.005). 
Histopathological examination displayed the average 
numbers of blood vessels (Figure 3). The average number 
of blood vessels was 145.1±55.0 in control group, 69.5±20.6 
in single-dose treatment group, and 43.7±22.6 in multiple-
dose treatment group. Multiple and single-dose bevacizumab 
treatment groups had significantly fewer blood vessels than 
the control group (P=0.001, and P=0.005, respectively). 
Additionally, multiple-dose bevacizumab treatment group 
had significantly fewer blood vessels compared to single-
dose bevacizumab treatment group (P=0.019). Regarding 
to evaluation of collagen formation evaluation with Masson 
trichrome staining, multiple and single-dose bevacizumab 
treatment groups showed more regular collagen formation than 
control group, however there was no statistical significance 
(P=0.159; Figure 4). 
Corneal inflammation and edema evaluation on histopathological 
examination were shown on Figure 5 and Table 3. The lowest 
corneal inflammation and edema grade was in multiple-
dose bevacizumab treatment group, followed by single-dose 
bevacizumab treatment group, and control group. Corneal 
inflammation grade was statistically lower in multiple-dose 
bevacizumab treatment group than control group (P=0.001). 
Although there was no statistical significance, corneal 
inflammation grade in multiple-dose bevacizumab treatment 
group was lower than single dose bevacizumab treatment 
group (P=0.130).
Figure 1 The degree of corneal neovascularization according to the groups.
Table 1 Corneal opacity grades according to groups as grade 0 
(none) to grade 4 (most intense)
Corneal opacity grades Group 1 Group 2 Group 3
Grade 0 4
Grade 1 1 3
Grade 2 4 6 3
Grade 3 4 2
Grade 4 2 1
Table 2 Corneal edema grades according to groups as grade 0 (no 
edema), grade 1 (mild to moderate edema) and grade 2 (severe edema)
Corneal edema grades Group 1 Group 2 Group 3
Grade 0 1 5
Grade 1 4 6 5
Grade 2 6 3
Figure 2 The histogram showing the mean percentage of corneal 
neovascularization area, which was significantly lower in 
multiple-dose bevacizumab treatment group than single-dose 
bevacizumab treatment group and control group.
Bevacizumab on rat corneal neovascularization
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DISCUSSION
In this study, we designed an experimental corneal 
neovascularization model in rats and applied single- or multiple-
dose subconjunctival bevacizumab injections to examine 
their effect on newly formed vessels, also compared their 
effect with control group. We observed that, in experimental 
animal model subconjunctival bevacizumab injections 
inhibited corneal neovascularization. Additionally, multiple-
dose bevacizumab injections were superior to the single-dose 
bevacizumab treatment in regards of effectiveness in inhibiting 
neovascularization and inflammation. 
Inflammation is seen in the cornea due to the etiology of 
neovascularization[17]. Inflammation is accompanied by cell 
chemotaxis, migration and proliferation in a controlled manner 
with proinflammatory and anti-inflammatory molecules[18]. 
Inflammation and angiogenesis are parallel at many 
points[17-19]. In the study of Amano et al[20], inflammation and 
VEGF increased with trauma in rat corneas and it was seen 
that inflammatory neovascularization was associated with 
VEGF. Several studies focused on the effects of anti-VEGF 
treatment in corneal neovascularization in either human or 
animal studies[11-15,21]. In an experimental study conducted 
by Bock et al[21], a model of corneal neovascularization with 
sutures was prepared in mice. In this study, inflammation-
induced angiogenesis and lymphangiogenesis were suppressed 
with bevacizumab[21]. In a rat corneal neovascularization 
model, Oh et al[17] showed that subconjunvtival bevacizumab 
reduced the inflammatory cell infiltration and proinflammatory 
cytokines such as interleukin (IL)-2, interferon (IFN) gamma 
and IL-6. In our study, where bevacizumab was evaluated for 
its effectiveness against inflammation, histopathologically it 
was observed that there was a statistically significant reduction 
in the intensity of inflammation in the bevacizumab-treated 
groups compared to the control group.
Some experimental studies evaluated the treatment timing 
of subconjunctival bevacizumab. Papathanissou et al[22] 
produced a corneal burn model in rabbits. In their study, 
3.75 mg subconjunctival bevacizumab injection was 
administered immediately and fourteen days after corneal 
burn, separately. They found early treatment group was more 
effective in suppressing corneal neovascularization than the 
late treatment group[22]. Hurmeric et al[13] showed the similar 
result that inhibition of corneal neovascularization in the early 
subconjunctival bevacizumab treatment group was significantly 
more successful than late treatment group. Henceforth, we 
designed our study to start the treatment immediately after 
creating chemical corneal burn. 
Yoeruek et al[15] created an experimental study in rabbit 
corneal burn. Corneal edema and opacity were evaluated 
with topical bevacizumab treatment in this study. When the 
corneal opacity was assessed, the treatment group had a lower 
grade of edema compared to the control group. However, no 
statistical difference was observed between the control group 
and treatment group when corneal edema was evaluated[15]. 
Similarly in the neovascularization model with chemical 
Table 3 The recorded corneal inflammation and edema grades 
were lower in multiple-dose bevacizumab treatment group
Corneal inflammation and 
edema grades Group 1 Group 2 Group 3
Grade 0 1 3
Grade 1 2 6 7
Grade 2 8 3
Figure 3 The average numbers of blood vessels was more prominent 
in Group 1 than Groups 2 and 3.
Figure 4 Collagen formation evaluation with Masson trichrome 
staining  In subconjunctival bevacizumab treatment groups (Groups 
2 and 3), collagen fibers were in more regular order.
Figure 5 Corneal inflammation and edema evaluation on 
histopathological examination  In the control group, edema and 
inflammation were more intense compared to the treatment groups.
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cauterization in rats, Dursun et al[23] reported that corneal 
edema and opacity grades in the bevacizumab treated groups 
were statistically lower than those in the control group. Our 
study showed that, the treatment group receiving multiple-
doses of bevacizumab had statistically significantly lower 
grades in corneal opacity and edema than the single-dose 
bevacizumab treatment group and control group. There was 
no statistically significant difference between single-dose 
bevacizumab treatment group and the control group, although 
corneal opacity and edema grades were lower in the single-
dose bevacizumab treatment group.
Edelman et al[24] found that the levels of VEGF mRNA and 
protein following chemical burns on rat corneas reached their 
highest levels after 48h, and their levels decreased to control 
levels by 7d. In an experimental study on rats, Kim et al[25] 
investigated the half-life of subconjunctivally administered 
bevacizumab, and observed that following injection, 
bevacizumab was first detected at 12th hour in aqueous humor, 
and the approximate half-life was 27h. So in our present study, 
instead of administering a single high-dose of bevacizumab 
at one time, we preferred to administer the agent in multiple 
doses. In this respect, we aimed to increase the duration of 
anti-VEGF effect in the tissue with repeated administration.
Lopes et al[26] investigated subconjunctival and topical 
bevacizumab efficacy in rabbits with corneal neovascularization. 
In this experimental study, both subconjunctival and topical 
bevacizumab showed an inhibitory effect on corneal 
neovascularization in rabbits’ eyes after chemical burning of 
the cornea[26]. In our experimental study, we observed that 
subconjunctival bevacizumab treatment, either as a single- 
or multiple-dose, resulted in better results compared to 
the controls in decreasing corneal edema, corneal opacity, 
area of corneal neovascularization, number of vessels, and 
inflammation status. When we compared Group 2 with Group 
3, we found the multiple-dose group to be more effective in 
decreasing corneal edema, corneal opacity, area of corneal 
neovascularization, and number of vessels, resulting in better 
suppression of corneal neovascularization.
In conclusion, we observed that subconjunctival bevacizumab 
administration was effective in suppressing and controlling 
experimental corneal neovascularization. We believe that, it 
should be administered as soon as possible following chemical 
burn. We observed that the results in inhibiting inflammation 
and neovascularization were better with multiple-dose 
application compared to the single-dose, probably by achieving 
a standard basal anti-VEGF level in the first few days. Thus, 
we consider giving bevacizumab in multiple doses should be 
preferred in the treatment protocol. However, there is still need 
for further prospective studies, in regards of determination 
of long term effects of bevacizumab in larger groups, and the 
proper dosing regimen.
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